Friday, September 22, 2017

Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR-T Therapy Axicabtagene...

Tailwinds' Take: CYRX holds a commanding position in the delivery of regenerative therapeutics. KITE's drug will be the second approved in this space. Expect...

Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma

Tailwinds' Take: CYRX is in a sweet spot and will be for at least the next couple of years as they will continue to...

Cryoport to Support Launch of Potential Treatment for Relapsed/Refractory Acute Lymphoblastic Leukemia

Tailwinds' Take: This announcement was well anticipated, but great news nonetheless. Revenue guidance of $8-10M per annum from this contract is double trailing 12...

Risk Management at Work: Trimming Cryoport

Since we bought CYRX, the stock has gone up close to 200%. In the process, it has become by far the largest position in...

What To Do With Cryoport After A 100% Gain?

Shares of CYRX have been the best performer in the Tailwinds Select Portfolio. Since we initiated coverage on March 28, 2017, the shares have...

Cryoport Biotech Activity Index “CoBRA Index” increases 30.1% in Q1 2017

IRVINE, Calif., June 19, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of...

Cryoport Expands Agreement with Sanaria to Support Grant Awards with U.S. National Institutes of...

Tailwinds' Take: CYRX's competitive strength will result in a number of partner relationships going forward as more trials move towards Phase III and commercialization.  IRVINE,...

Novartis FDA Review Date Pushes Cryoport Shares

This morning the FDA posted a note on their website that they would be having a panel review of Novartis' CAR-T therapy CTL019 (tisagenlecleucel-T) on...
video

The Cryoport (CYRX) Investment Thesis

This video details the competitive strength and upcoming catalysts for CYRX.

Cryoport: Delivering Results

I often refer to Silicon Valley as having a printing press for making money. It literally seems to grow on trees not only down...

Cryoport Revenue Grows by 74%, Driven by Biopharma

Tailwinds' Take: 27 new clients and 14 new trials demonstrates the strength of their competitive positioning in the growing biopharma space. The company is...

Cryoport Added to the Tailwinds Select Portfolio

As of this morning, at $2.09 per share, we have added Cryoport (CYRX) to the Tailwinds Select Portfolio. Cryoport is in the business of shipping...

Cryoport Announces Proposed Public Offering of Common Stock

Tailwinds' Take: This transaction will provide the needed cash to see CYRX through to cash-flow positive, an event that will happen in either the...

Cryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31,...

Tailwind's Take: this is a $2B market potentially and CYRX is the only pure play, fastest growing and best offering in the space. This could...

Cryoport Launches the “CoBRA Index” for a Comprehensive Measure of Activity in the Regenerative...

Tailwind's Take: by publishing this index, investors in CYRX have a unique view into the growth of their industry. Expect this index to remain...

Moffitt Cancer Center Taps Cryoport As Exclusive Cryogenics Logistics Provider

Tailwinds' Take: Moffitt is one of the leading cancer institutes in the US. Their selection of Cryoport is a major endorsement for the company...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address